Multus Biotechnology Limited

Multus Biotechnology is redefining cell culture media for the future of biomanufacturing. Using AI, high-throughput automation, and proprietary ingredient libraries, Multus accelerates the design of high-performance, animal-free formulations tailored to specific cell types. These formulations are critical for scaling up the production of next-generation foods, materials, and medicines—from cultivated meat to regenerative therapies.

Our AI-enabled platform, MediOP™, cuts development timelines from years to months while improving cell growth performance, supply chain security, and regulatory readiness. We’ve launched six commercial products, including the world’s first food-grade basal medium, and operate an FSSC 22000-certified production facility in London. Our media is in use or under evaluation by biomanufacturing companies across Europe, North America, and Asia. Partnerships with global players like Bühler, Charoen Pokphand Foods, and leading CDMOs underscore the scalability and relevance of our solutions.

With the global bioeconomy expected to exceed $4 trillion by 2030, feedstock innovation is now a strategic priority. Multus is uniquely positioned to power this transition by turning media from a bottleneck into a competitive advantage. We are now raising our Series A round to scale operations, expand into Asia and the US, and bring our AI-powered media development platform to the heart of therapeutic and food-grade manufacturing.